CDSCO Has Given Approval for 2 Cancer Drugs of AstraZeneca

  • AstraZeneca’s Trastuzumab deruxtecan has been approved in India for treating adult patients with unresectable or metastatic HER2-Low breast cancer post-chemotherapy. 
  • The drug is also approved for individuals with HER2-positive gastric or gastroesophageal cancer following a trastuzumab-based regimen. 
  • The approval is a significant step towards addressing unmet medical needs and offering transformative treatments to Indian patients. 
  • The drug has shown significant advancements in overall and progression-free survival for HER2-low metastatic breast cancer and as a second-line therapy for HER2-positive advanced gastric or gastroesophageal junction cancer.
Posted in Current Affairs.

Leave a Reply

Your email address will not be published. Required fields are marked *